Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2005

01-09-2005 | Letter to the Editor

Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease

Authors: Huseyin T. E. Ozer, Eren Erken, Ramazan Gunesacar, Oguz Kara

Published in: Rheumatology International | Issue 6/2005

Login to get access

Excerpt

Behçet’s disease (BD) is a multisystemic vasculitis of unknown etiology characterized by oral and genital ulceration and eye, skin, joint, gastrointestinal, and neurological manifestations. Besides elevated levels of tumor necrosis factor alpha (TNF-α) in sera of patients with BD [1], increased TNF-α and interleukin (IL)-1 production has been shown in lipopolysaccharide-stimulated peripheral blood monocytes [2]. Additionally, TNF-α and IL-1β mRNA have been shown to be increased in attack-free periods in patients with familial Mediterranean fever (FMF) [3]. …
Literature
1.
Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S (1996) Cytokines in Behçet’s disease. J Rheumatol 23:321–322PubMed
2.
Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, Ocal L, Inanc M, Capo C (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549PubMed
3.
Notarnicola C, Didelot MN, Seguret F, Demaille J, Touitou I (2002) Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun 3:43–45CrossRefPubMed
4.
Dinarello CA, Moldaver LL (2000) Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. Amgen, Thousand Oaks, pp 99–110
5.
Kaburaki T, Fujino Y, Kawashima H, Merino G, Numaga J, Chen J, Matsushima K (2003) Plasma and whole-blood chemokine levels in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 241:353–358PubMed
6.
Eisenberg S, Aksentijevich I, Deng Z, Kastner DL, Matzner Y (1998) Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med 129:539–542PubMed
7.
Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1) and Th2. J Exp Med 187:129–134CrossRefPubMed
8.
Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974CrossRefPubMed
9.
10.
Ortiz BD, Nelson RJ, Krensky AM (1997) Switching gears during T-cell maturation: RANTES and late transcription. Immunol Today 18:468–471CrossRefPubMed
11.
Bacon KB, Premack BA, Gardner P, Schall TJ (1995) Activation of dual T cell pathways by the chemokine RANTES. Science 269:1727–1730PubMed
Metadata
Title
Serum RANTES, MIP-1α, and MCP-1 levels in Behçet’s disease
Authors
Huseyin T. E. Ozer
Eren Erken
Ramazan Gunesacar
Oguz Kara
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0519-0

Other articles of this Issue 6/2005

Rheumatology International 6/2005 Go to the issue

Original Article

Arthritis or vasculitis as presenting symptoms of Crohn’s disease

Original Article

A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis

Original Article

The effect of infliximab on extraintestinal manifestations of Crohn’s disease

Letter to the Editor

Osteoporosis fracture liaison experience: the Belfast experience

Original Article

Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet’s disease

Original Article

Pulmonary involvement in rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits